Xintela AB (publ) (XINT.ST)
SEK 0.37
(4.52%)
SEK 0.37
(4.52%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -53.47 Million SEK | 15.84% |
| 2022 | -64.82 Million SEK | -63.39% |
| 2021 | -57.1 Million SEK | -32.32% |
| 2020 | -30.32 Million SEK | 10.58% |
| 2019 | -33.91 Million SEK | -53.44% |
| 2018 | -22.1 Million SEK | -3.97% |
| 2017 | -21.26 Million SEK | -28.53% |
| 2016 | -16.54 Million SEK | -49.41% |
| 2015 | -11.07 Million SEK | -277.25% |
| 2014 | -7.38 Million SEK | -32.03% |
| 2013 | -2.22 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -10.59 Million SEK | 5.72% |
| 2024 Q2 | -10.17 Million SEK | 3.91% |
| 2023 Q1 | -14.27 Million SEK | 36.77% |
| 2023 Q4 | -11.94 Million SEK | -5.26% |
| 2023 FY | - SEK | 15.84% |
| 2023 Q3 | -11.35 Million SEK | 31.7% |
| 2023 Q2 | -16.61 Million SEK | -16.44% |
| 2022 Q4 | -22.56 Million SEK | -96.85% |
| 2022 Q3 | -11.46 Million SEK | 30.53% |
| 2022 Q2 | -16.5 Million SEK | -9.16% |
| 2022 Q1 | -15.11 Million SEK | -33.87% |
| 2022 FY | - SEK | -63.39% |
| 2021 FY | - SEK | -32.32% |
| 2021 Q4 | -11.29 Million SEK | -13.78% |
| 2021 Q1 | -8.1 Million SEK | 20.38% |
| 2021 Q3 | -9.92 Million SEK | 8.2% |
| 2021 Q2 | -10.81 Million SEK | -33.45% |
| 2020 FY | - SEK | 10.58% |
| 2020 Q1 | -6.65 Million SEK | 2.48% |
| 2020 Q3 | -6.2 Million SEK | 14.79% |
| 2020 Q4 | -10.17 Million SEK | -63.97% |
| 2020 Q2 | -7.28 Million SEK | -9.37% |
| 2019 Q4 | -6.82 Million SEK | 10.52% |
| 2019 Q3 | -7.63 Million SEK | 26.11% |
| 2019 Q2 | -10.32 Million SEK | -13.1% |
| 2019 Q1 | -9.13 Million SEK | -27.67% |
| 2019 FY | - SEK | -53.44% |
| 2018 FY | - SEK | -3.97% |
| 2018 Q4 | -7.15 Million SEK | -100.96% |
| 2018 Q3 | -3.55 Million SEK | 20.81% |
| 2018 Q2 | -4.49 Million SEK | 34.87% |
| 2018 Q1 | -6.9 Million SEK | -7.78% |
| 2017 Q4 | -6.4 Million SEK | -35.92% |
| 2017 FY | - SEK | -28.53% |
| 2017 Q1 | -5.27 Million SEK | -14.12% |
| 2017 Q2 | -4.87 Million SEK | 7.44% |
| 2017 Q3 | -4.71 Million SEK | 3.44% |
| 2016 FY | - SEK | -49.41% |
| 2016 Q1 | -3.51 Million SEK | 25.92% |
| 2016 Q4 | -4.61 Million SEK | -74.86% |
| 2016 Q3 | -2.64 Million SEK | 43.18% |
| 2016 Q2 | -4.64 Million SEK | -32.2% |
| 2015 Q3 | -1.79 Million SEK | 31.94% |
| 2015 Q2 | -2.63 Million SEK | -16.35% |
| 2015 Q1 | -2.26 Million SEK | 0.0% |
| 2015 FY | - SEK | -277.25% |
| 2015 Q4 | -4.74 Million SEK | -164.55% |
| 2014 FY | - SEK | -32.03% |
| 2013 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 85.462% |
| Camurus AB (publ) | 562.54 Million SEK | 109.505% |
| Mendus AB (publ) | -97.84 Million SEK | 45.352% |
| Lipum AB (publ) | -37.11 Million SEK | -44.053% |
| NextCell Pharma AB | -40.98 Million SEK | -30.464% |
| Simris Alg AB (publ) | -22.36 Million SEK | -139.105% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -212.979% |
| Active Biotech AB (publ) | -43.88 Million SEK | -21.838% |
| Amniotics AB (publ) | -27.14 Million SEK | -96.997% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -276.106% |
| BioArctic AB (publ) | 275.38 Million SEK | 119.417% |
| Cantargia AB (publ) | -284.31 Million SEK | 81.193% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -173.104% |
| CombiGene AB (publ) | -35.33 Million SEK | -51.321% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 62.037% |
| Genovis AB (publ.) | 64.57 Million SEK | 182.808% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 53.466% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -44.423% |
| Intervacc AB (publ) | -68.98 Million SEK | 22.483% |
| Kancera AB (publ) | -61.88 Million SEK | 13.602% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -99.645% |
| LIDDS AB (publ) | -39.67 Million SEK | -34.79% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -341.763% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 270.268% |
| OncoZenge AB (publ) | 7.26 Million SEK | 835.907% |
| Saniona AB (publ) | -69.69 Million SEK | 23.279% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 83.157% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 81.041% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 68.512% |
| Ziccum AB (publ) | -20.34 Million SEK | -162.86% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 2673650.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 77.497% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -2470.721% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -298.116% |
| Corline Biomedical AB | -1.69 Million SEK | -3062.093% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 69.15% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 2.436% |
| Aptahem AB (publ) | -10 Million SEK | -434.217% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 562.992% |
| Fluicell AB (publ) | -25.91 Million SEK | -106.34% |
| Biovica International AB (publ) | -119.5 Million SEK | 55.257% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -26.637% |
| AcouSort AB (publ) | -16.7 Million SEK | -220.128% |
| Abliva AB (publ) | -93.6 Million SEK | 42.878% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 83.243% |
| 2cureX AB (publ) | -35.13 Million SEK | -52.183% |
| I-Tech AB | 30.34 Million SEK | 276.21% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 92.517% |
| Cyxone AB (publ) | -20.41 Million SEK | -161.933% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 47.809% |
| Biosergen AB | 228 Thousand SEK | 23552.193% |
| Nanologica AB (publ) | -62.11 Million SEK | 13.922% |
| SynAct Pharma AB | -222.7 Million SEK | 75.99% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -21.91% |
| BioInvent International AB (publ) | -312.7 Million SEK | 82.901% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 17381.433% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 127414.936% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 76.915% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -506.765% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 50.744% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -366.222% |